Compare Abeona Therapeutics Inc (ABEO) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs BlackRock TCP Capital Corp — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while BlackRock TCP Capital Corp trades at $3.16 (market cap $268.49M). The key difference: Abeona Therapeutics Inc is the larger of the two by market cap, and BlackRock TCP Capital Corp pays a 26.25% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | TCPC | |
|---|---|---|
Market Cap | $373.32M | $268.49M |
Sector | Health | Financials |
52-Week High | $7.23 | $7.90 |
52-Week Low | $4.17 | $3.14 |
Enterprise Value | $228.22M | — |
Dividend Yield | — | 26.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
TCPC trades at $3.25, down 3.27% on the day, with a bearish technical outlook and negative revenue trends. The stock shows a low price-to-book ratio of 0.48 but faces challenges with negative net income and declining profitability. Recent news highlights a shareholder investigation into fiduciary duties, adding to investor concerns amid mixed analyst sentiment.
The outlook remains cautious due to persistent losses and legal scrutiny. Opportunities exist from the discounted book value and dividend yield, but risks from earnings misses and negative cash flow outweigh near-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
